Moderna
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company...
An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT05295433
- Locations
- πΊπΈ
UCLA Medical Center, Los Angeles, California, United States
πΊπΈLucile Packard Children's Hospital at Stanford, Palo Alto, California, United States
π¨π¦Stollery Children's Hospital University of Alberta, Edmonton, Alberta, Canada
A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19
- Conditions
- Interventions
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 3548
- Registration Number
- NCT05249829
- Locations
- π¬π§
Halton General Hospital, Runcorn, Cheshire, United Kingdom
π¬π§Salford Royal Hospital - PPDS, Salford, Manchester, United Kingdom
π¬π§University College London Hospitals Covid-19 Vaccine Centre, London, Middlesex, United Kingdom
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
- Conditions
- Interventions
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 842
- Registration Number
- NCT05164094
- Locations
- πΊπΈ
Ventavia Research Group, Houston, Texas, United States
πΊπΈDM Clinical Research - Texas Center For Drug Development - ERN - PPDS, Houston, Texas, United States
πΊπΈMedical Affiliated Research Institute, Huntsville, Alabama, United States
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters
- Conditions
- Interventions
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 540
- Registration Number
- NCT05137236
- Locations
- πΊπΈ
Coastal Carolina Research Center, North Charleston, South Carolina, United States
πΊπΈACRC Trials, Frisco, Texas, United States
πΊπΈMeridian Clinical Research (Nebraska), Lincoln, Nebraska, United States
A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05130437
- Locations
- πΊπΈ
The Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
πΊπΈUniversity of Michigan Hospitals, Ann Arbor, Michigan, United States
π¨π¦Hospital For Sick Children, Toronto, Ontario, Canada
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults β₯60 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 36814
- Registration Number
- NCT05127434
- Locations
- πΊπΈ
HEALOR Primary Care - Physicians Las Vegas - CCT, Las Vegas, Nevada, United States
πΊπΈVelocity Clinical Research - Cincinnati - PPDS, Cincinnati, Ohio, United States
πΊπΈAES - DRS - Synexus Clinical Research US, Inc. - Cincinnati, Cincinnati, Ohio, United States
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05105048
- Locations
- πΊπΈ
California Research Foundation, San Diego, California, United States
πΊπΈEast-West Medical Research Institute, Honolulu, Hawaii, United States
πΊπΈVelocity Clinical Research, North Hollywood, California, United States
A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05095727
- Locations
- πΊπΈ
University of Connecticut Health Center, Farmington, Connecticut, United States
πΊπΈChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
πΊπΈBaylor College of Medicine, Houston, Texas, United States
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 7454
- Registration Number
- NCT05085366
- Locations
- πΊπΈ
CVS HealthHub - Atlanta S, Atlanta, Georgia, United States
πΊπΈCVS HealthHub - Atlanta, Atlanta, Georgia, United States
πΊπΈAventiv Research Inc., Columbus, Ohio, United States
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 291
- Registration Number
- NCT04975893
- Locations
- πΊπΈ
Johnson County Clin-Trials, Inc., Lenexa, Kansas, United States
πΊπΈOptimal Research, LLC, Peoria, Illinois, United States
πΊπΈTekton Research Inc, Austin, Texas, United States